{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:21:59Z","timestamp":1774678919398,"version":"3.50.1"},"reference-count":11,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,4,12]]},"DOI":"10.1001\/jama.2022.2360","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:30:41Z","timestamp":1649093441000},"page":"1341","source":"Crossref","is-referenced-by-count":2,"title":["Heart Failure, Precision Medicine, and Incremental Equity"],"prefix":"10.1001","volume":"327","author":[{"given":"Melvin R.","family":"Echols","sequence":"first","affiliation":[{"name":"Morehouse School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Taylor","sequence":"additional","affiliation":[{"name":"Morehouse School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"8","key":"jed220007r1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America.","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"key":"jed220007r2","article-title":"Association of transthyretin Val122Ile variant with incident heart failure among Black individuals.","author":"Parcha","journal-title":"JAMA"},{"issue":"8","key":"jed220007r3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","article-title":"Understanding the complexity of heart failure risk and treatment in Black patients.","volume":"13","author":"Nayak","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"4","key":"jed220007r4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11912-021-01028-8","article-title":"Updates in cardiac amyloidosis diagnosis and treatment.","volume":"23","author":"Stern","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"jed220007r5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jchf.2021.09.006","article-title":"Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in Black adults.","volume":"10","author":"Coniglio","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"2","key":"jed220007r6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.v23.2","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"jed220007r7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).","volume":"141","author":"Hanna","year":"2021","journal-title":"Am J Cardiol"},{"issue":"11","key":"jed220007r8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"jed220007r9","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry.","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"jed220007r10","first-page":"1","article-title":"Association of the V122I transthyretin amyloidosis genetic variant with cardiac structure and function in middle-aged Black adults: Coronary Artery Risk Development in Young Adults (CARDIA) study.","volume":"6","author":"Sinha","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"8","key":"jed220007r11","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41436-021-01171-4","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).","volume":"23","author":"Miller","year":"2021","journal-title":"Genet Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2790714\/jama_echols_2022_ed_220007_1649695538.89776.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T17:02:01Z","timestamp":1649782921000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2790714"}},"subtitle":["The Case of Hereditary Amyloid Cardiomyopathy"],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":11,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,4,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.2360","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}